FDA’s warning letter to Tides Medical illustrates how a device’s intended use, not its manufacturer’s chosen product code, determines its regulatory requirements
Can a medical device manufacturer classify an innovative wound-treatment technology as a Class I device exempt from FDA premarket review? That question is at the center of an October 6, 2026, FDA warning letter to Tides Medical LLC concerning its APLICOR 3D system.
According to FDA, Tides Medical has been commercially distributing APLICOR 3D without the necessary marketing clearance or approval. The company, however, maintained that its product was a Class I device exempt from premarket notification requirements.
The disagreement illustrates a fundamental principle of medical device regulation, that a manufacturer’s claimed device classification must be supported by the product’s intended use.
A liquid medication dispenser, or something more?
Tides Medical identified APLICOR 3D as a liquid medication dispenser under 21 CFR 880.6430, product code KYX. That regulation describes a device used to dispense a measured amount of liquid medication. Devices within this classification are generally Class I and exempt from premarket notification, subject to applicable limitations.
But FDA identified a significant difference between that definition and how Tides Medical marketed APLICOR 3D. According to the company’s promotional materials cited in the warning letter, APLICOR 3D is a personalized 3D bioprinting system that uses a patient’s own adipose (fat) tissue to create customized grafts for wound treatment.
The company promoted the technology for acute and chronic wounds, including diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and traumatic wounds. FDA concluded that these intended uses differ substantially from those of a conventional liquid medication dispenser.
Why the Class I exemption did not apply
FDA cited 21 CFR 880.9, which establishes limitations on exemptions from premarket notification requirements. Under this provision, a device may lose its exemption when its intended use differs from the intended use of legally marketed devices within the exempt classification.
In other words, identifying an existing Class I product code does not automatically establish that a new product qualifies for that classification or its associated exemption. And FDA determined that APLICOR 3D exceeded those limitations because of its advertised clinical applications.
The agency consequently identified the product as adulterated under Section 501(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act because it lacked an approved premarket approval application (PMA) or investigational device exemption (IDE). FDA also cited misbranding under Section 502(o) for failure to satisfy applicable premarket notification requirements.
Although the letter identifies the absence of a PMA or IDE, it does not provide a comprehensive classification determination identifying a specific Class III regulation or product code.
The importance of marketing claims
One particularly instructive aspect of this case is FDA’s reliance on the manufacturer’s own promotional statements. FDA reviewed the Tides Medical website and cited descriptions of APLICOR 3D’s ability to transform autologous adipose tissue into personalized grafts for treating wounds. The statements were central to FDA’s assessment of the device’s intended use.
For manufacturers developing innovative technologies, this is an important reminder that regulatory classification cannot be considered independently of product labeling, advertising, and promotional claims. A product’s technological characteristics matter, but so does what the manufacturer claims the product is intended to accomplish.
A regulatory disagreement months in the making
The warning letter also acknowledges correspondence from Tides Medical dated February 26, 2026, responding to a letter issued by FDA’s Center for Devices and Radiological Health (CDRH) the previous day. This indicates that the company and FDA had communicated about the matter months before the October warning letter.
CBER, the Center for Biologics Evaluation and Research, ultimately issued the warning letter, an interesting aspect of a case involving technology that processes human adipose tissue to create wound grafts. The letter, however, specifically identifies violations of medical device requirements rather than establishing a separate biological product classification.
FDA directed Tides Medical to cease activities resulting in the adulteration or misbranding of APLICOR 3D, including commercial distribution for the cited uses. The agency requested a written response within 15 business days of receipt, explaining corrective actions and measures to prevent recurrence.
The regulatory lesson
The Tides Medical warning letter illustrates a recurring challenge in medical device innovation: emerging technologies do not always fit neatly within established regulatory classifications.
Manufacturers must evaluate their products’ actual intended uses, technological characteristics, applicable classification regulations, and available regulatory pathways before concluding that a device qualifies for a particular classification or exemption.
For novel technologies, early engagement with FDA may help resolve uncertainty before commercial distribution begins. The lesson is straightforward: Selecting a product code does not determine a device’s regulatory classification. The product’s intended use and applicable regulatory requirements do.
